DoorDash (NYSE:DASH) reported quarterly sales of $1.30 billion which beat the analyst consensus estimate of $1.28 billion by 1.56 percent. This is a 34.02 percent increase over sales of $970.00 million the same period last year.
ImmunityBio Announces FDA Acceptance Of Biologics License Application For N-803 In BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ
The FDA accepted for review a Biologics License Application (BLA) from ImmunityBio, Inc. ((IBRX), for its antibody cytokine fusion protein as a treatment for patients with BCG-unresponsive non-muscle-invasive bladder
